Heron Therapeutics Inc. (HRTX)
NASDAQ: HRTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
HRTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $48.04M
- EPS (TTM)
- -$0.11
- Dividend yield
- None
- 52-week range
- 0.2479 – 1.58
- Day range
- 0.2479 – 0.2695
- Volume / Avg
- 1.75M / 4.56M
- Beta
- —
- Shares outstanding
- 190.27M
52-week range
HRTX stock today
Heron Therapeutics (HRTX) closed at $0.2525 on Nov 20, down 4.39% (-$0.0116), versus the S&P 500's 3.70% decline. Trading was light, with 1.75M shares changing hands, about 38% of the average daily volume. At this level, HRTX sits near the bottom of its 52-week range of $0.2479 to $1.58: 84.0% below the high, set on Jan 9, 2026 and 1.9% above the low.
HRTX is down 80.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 76.2%. Heron Therapeutics has posted a net loss over the last twelve months (EPS of -$0.11), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Heron Therapeutics
Company profileHeron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Craig Alexander Collard
- Headquarters
- Cary, NC
- Employees
- 128
- Website
- herontx.com
Financial highlights
Full financialsIn fiscal 2025, Heron Therapeutics generated $154.9 million in revenue, up 7.4% from fiscal 2024, its 4th consecutive year of revenue growth. Heron Therapeutics reported a net loss of $20.2 million, compared with a loss of $13.6 million a year earlier. Gross margin was 73.3% (up from 73.2%) and operating margin -1.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $154.90M | $144.28M | $127.04M | $107.67M | $86.35M |
| Growth | +7.36% | +13.57% | +17.99% | +24.70% | -2.59% |
| Net income | $-20.20M | $-13.58M | $-110.56M | $-182.02M | $-220.68M |
| EPS (diluted) | $-0.12 | $-0.09 | $-0.80 | $-1.67 | $-2.24 |
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$7.00+2672.28%
- Strong buy 0
- Buy 0
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.05 vs $-0.03
- Surprise
- -66.67%
HRTX news
All HRTX news- CRMD to Acquire HRTX Assets for $223M Upfront to Expand PortfolioNasdaqCRMD, TGTX, HRTX, AMRX
- Heron Therapeutics Announces Third Quarter 2026 Financial ResultsGlobeNewswire
- CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of CareGlobeNewswire
- Heron Therapeutics to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026GlobeNewswire
- CytoDyn Appoints Robert E. Hoffman As CEO; Lalezari To Focus On ResearchNasdaqANAB, HRTX, SUN
- Notable Wednesday Option Activity: HRTX, GLNG, KNSLNasdaqHRTX, GLNG, KNSL
Heron Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RFLRafael Holdings Inc. Class B | 0.9197 | +2.19% | $47.99M | vs HRTX |
| ONCYOncolytics Biotech Inc. | 0.3501 | -10.37% | $47.66M | vs HRTX |
| NMADNomad Power Solutions Inc. | 2.56 | +13.53% | $47.15M | vs HRTX |
| VRCAVerrica Pharmaceuticals Inc. | 2.74 | -5.03% | $47.07M | vs HRTX |
| ACRVAcrivon Therapeutics Inc. | 1.15 | -17.86% | $49.35M | vs HRTX |
| TNXPTonix Pharmaceuticals Holding Corp. | 2.38 | -6.67% | $46.25M | vs HRTX |
| MISTMilestone Pharmaceuticals Inc. | 0.3711 | -7.06% | $46.20M | vs HRTX |
| HOWLWerewolf Therapeutics Inc. | 0.9466 | -3.97% | $46.00M | vs HRTX |
Indexes, lists and sector
Heron Therapeutics stock FAQ
What is Heron Therapeutics's stock price today?
HRTX last traded at $0.2525 as of Nov 20, 4:00 PM EST, down 4.39% on the day. Prices are delayed at least 15 minutes.
Does Heron Therapeutics pay a dividend?
No. Heron Therapeutics does not currently pay a regular cash dividend.
Who is Heron Therapeutics's CEO?
Mr. Craig Alexander Collard is the chief executive officer of Heron Therapeutics Inc., which has about 128 employees.
Has HRTX ever split its stock?
Yes. The most recent HRTX stock split was a 1-for-20 split on Jan 13, 2014, one of 2 splits on record.
What is the HRTX 52-week high?
The 52-week high for HRTX is $1.58 and the 52-week low is $0.2479. The stock is currently 84.0% below its high.